Navigation Links
Nuvelo Announces Upcoming Conference Calls, Webcasts and Conference Participation

SAN CARLOS, Calif., Feb. 7 /PRNewswire-FirstCall/ -- Nuvelo, Inc. (Nasdaq: NUVO) today announced that it will hold the following events in February:

BIO CEO & Investor Conference

February 13, 2008

11:45 a.m. ET

Dr. Ted W. Love, Chairman and CEO

Fourth Quarter and Year End 2007 Financial Results and Accomplishments

Conference Call & Webcast

February 27, 2008

4:30 p.m. ET (1:30 p.m. PT)

Dr. Ted W. Love, Chairman and CEO

Dr. Michael Levy, EVP, Research and Development

Lee Bendekgey, SVP, Finance and CFO

Dial in: 866-854-8095 domestic and 706-634-8567 international with

passcode 32403438

Replay: 800-642-1687 domestic and 706-645-9291 international with passcode

32403438, available through Wednesday, March 12, 2008

Webcast: This call is being webcast by Thomson/CCBN and can be accessed via Nuvelo's website at The webcast is also being distributed through the Thomson StreetEvents Network. Individual investors can listen to the call at, Thomson's individual investor portal, powered by StreetEvents. Institutional investors can access the call via Thomson StreetEvents (, a password-protected event management site.

Live audio webcasts of the events and presentations will also be available online via the Investor Relations portion of Nuvelo's website at

About Nuvelo

Nuvelo, Inc. is dedicated to improving the lives of patients through the discovery, development and commercialization of novel drugs for acute cardiovascular disease, cancer and other debilitating medical conditions. Nuvelo's development pipeline includes alfimeprase, a direct acting fibrinolytic in Phase 2 clinical development for the treatment of thrombotic-related disorders including acute ischemic stroke and catheter occlusion; NU172, a direct thrombin inhibitor in Phase 1 development for use as a potential short-acting anticoagulant during medical or surgical procedures; and preclinical candidate NU206, a Wnt pathway modulator for the potential treatment of chemotherapy/radiation therapy-induced mucositis and inflammatory bowel disease. In addition, Nuvelo expects to continue its research programs in leukemia and lymphoma therapeutic antibodies and Wnt signaling pathway therapeutics to further expand its pipeline and create additional partnering and licensing opportunities.

Information about Nuvelo is available at our website at or by phoning 650-517-8000.

SOURCE Nuvelo, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Nuvelo Announces Upcoming Conference Calls, Webcasts and Conference Participation
2. HHS Announces $75 Million in Supplemental Funding to States for Pandemic Flu Preparedness
3. CRC Health Group Announces Acquisition of Bayside Marin Recovery Center, San Rafael
4. UHW Announces: Antelope Valley Hospital Caregivers and Board Vote to Ratify First Union Contract With SEIU UHW-West
5. HEI, Inc. Announces Sale of RFID Division Assets
6. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
7. Mettler-Toledo International Inc. Announces Webcast of Presentation at Thomas Weisel Partners 2007 Healthcare Conference
8. Z Trim Announces Revocation of Gregory Halpern Severence Agreement
9. Brooke Franchise Corporation Announces Selected July Results
10. Manor Care, Inc. Announces Record Date for Special Stockholder Meeting
11. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Adipex-P(R)
Post Your Comments:
(Date:11/30/2015)... ... November 30, 2015 , ... At Grand Dental PC, their priority ... , When you have dental problems, you need to turn to a dentist who ... and treat your needs, a friendly dentist who counsels you on the best ways ...
(Date:11/30/2015)... ... November 30, 2015 , ... Newly reviewed ... of Glen Ridge, NJ. He has both advanced training and considerable experience ... is also an expert in cosmetic dentistry. He is an active Spear ...
(Date:11/30/2015)... ... November 30, 2015 , ... ”Dying Words: The AIDS Reporting of Jeff Schmalz ... 2015, to coincide with World AIDS Day. The multi-media project will be in audio ... epidemic as he was dying of the disease. , A collaborative effort led by ...
(Date:11/30/2015)... ... 30, 2015 , ... Brenntag Specialties, Inc. (BSI) has been ... Nutraceutical Specialties products into oral solid dosage in the over the counter vitamin ... pleased to announce our expanded distribution agreement with ASI.” said Steve Brauer, President ...
(Date:11/30/2015)... PITTSBURGH, PA (PRWEB) , ... November 30, 2015 , ... ... quality of life in the womb. "My last baby had high blood pressure due ... way for mothers to protect their babies from noise pollution as well as radio ...
Breaking Medicine News(10 mins):
(Date:11/30/2015)... MOUNTAIN VIEW, Calif. , Nov. 30, ... has been the norm in U.S. medical ... obsolete. The increasingly popular accountable care payer-provider ... payment models and, in their wake, alter ... or quality-based payments will push forward new ...
(Date:11/30/2015)... LAKE, N.J. and SAN DIEGO ... and Arena Pharmaceuticals, Inc. (NASDAQ: ARNA ) today ... has accepted for filing the New Drug Application (NDA) ... the extended release formulation will offer patients a chronic ... ® ) is currently approved as an ...
(Date:11/30/2015)... MOUNTLAKE TERRACE, Wash. and ST. ... Cross and Express Scripts (NASDAQ: ESRX ) today ... benefit agreement. The partnership, which began in 1999, will ... --> --> After evaluating pharmacy ... process, Premera concluded that Express Scripts continues to offer ...
Breaking Medicine Technology: